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Introduction: There are no empiric data to support guidelines for
duration of therapy with antidementia drugs. This study examined
whether persistent use of antidementia drugs slows clinical
progression of Alzheimer disease (AD) assessed by repeated
measures on serial tests of cognition and function.
Methods:  Six hundred forty-one probable AD patients were
followed prospectively at an academic center over 20 years.
Cumulative drug exposure was expressed as a persistency index
(PI) reflecting total years of drug use divided by total years of
disease symptoms. Baseline and annual testing consisted of Mini-
Mental State Examination (MMSE), Alzheimer’s Disease Assess-
ment Scale-Cognitive Subscale (ADAS-Cog), Baylor Profound
Mental Status Examination (BPMSE), Clinical Dementia Rating-
Sum of Boxes (CDR-SB), Physical Self-Maintenance Scale
(PSMS), and Instrumental Activities of Daily Living (IADL). Annual
change in slope of neuropsychological and functional tests as
predicted by follow-up time, PI, and the interaction of these two
variables was evaluated.
Results: PI was associated with significantly slower rates of decline
(with, without adjustment for covariates) on MMSE (P <0.0001),
PSMS (P <0.05), IADL (P <0.0001), and CDR-SB (P <0.001).
There was an insignificant trend (P = 0.053) for the PI to be
associated with slower rate of decline on BPMSE. The association
of PI with ADAS-Cog followed a quadratic trend (P <0.01).
Analysis including both linear and quadratic terms suggests that PI
slowed ADAS-Cog decline temporarily. The magnitude of the
favorable effect of a rate change in PI was: MMSE 1 point per year,
PSMS 0.4 points per year, IADL 1.4 points per year, and CDR-SB
0.6 points per year. The change in mean test scores is additive
over the follow-up period (3 ± 1.94 years).
Conclusions: Persistent drug treatment had a positive impact on
AD progression assessed by multiple cognitive, functional, and
global outcome measures. The magnitude of the treatment effect
was clinically significant. Positive treatment effects were even
found in those with advanced disease.
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Introduction
Since 1993, five drugs have been marketed for the treatment
of Alzheimer disease (AD). These treatments are sometimes
regarded as having only ‘symptomatic’ rather than ‘disease-
modifying’ effects, although the utility of this distinction has
been questioned [1]. The first cholinesterase inhibitor (ChEI)
approved specifically to treat symptoms of AD was tacrine,
but it is no longer used. Galantamine and rivastigmine (both
approved for use in mild to moderate AD) and donepezil
(approved for use in mild to severe AD) are reported to
benefit cognition, function, and behavior in AD patients [2-9].
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lasting up to 1 year [10,11] in mild to moderate AD, and
6-month studies have reported that therapy is efficacious in
severe and institutionalized patients [12-15]. One controlled
2-year study (AD2000) evaluated mild to moderate AD
patients and found no significant differences between
patients who took donepezil compared with placebo in insti-
tutionalization rates or progression to disability, but significant
cognitive and functional effects were maintained in those who
received active treatment, despite methodological flaws
[16,17].
Memantine modulates glutamate via N-methyl-D-aspartate
(NMDA) receptor antagonism and was approved for treat-
ment of moderate to severe AD based upon three pivotal
trials. The first was a 12-week study of nursing home residents
[18]. In a 7-month study, memantine monotherapy compared
with placebo was beneficial [19], and in a 6-month trial,
combination therapy with memantine plus donepezil was
superior to placebo plus donepezil [20]. A recently published
24-week trial that also evaluated moderate to severe AD
patients suggested a weaker treatment effect with memantine
monotherapy; treatment was not associated with significant
overall cognitive or global changes in this trial, although there
were apparent benefits at intermediate time points [21].
Observations from the pivotal trials indicate that early
initiation of treatment is associated with greater long-term
benefit and that withdrawal and re-initiation of treatment is
detrimental [22].
Observational studies suggest that these drugs may benefit
cognition for a year [23] or slow time to dementia-related
nursing home placement [24,25]. Two recent studies have
evaluated the long-term use of a ChEI alone compared with a
drug regimen including both a ChEI and memantine. In one
study, AD patients followed for an average of 30 months
taking a ChEI plus memantine had slower cognitive and
functional decline compared with those taking only a ChEI or
those receiving no treatment [26]. In another study, AD
patients followed for an average of 5 years had significant
delay until nursing home admission if they had used a ChEI,
and the effect was significantly augmented if they had used a
ChEI plus memantine [27]. The ethical dilemma of prolonged
exposure to placebo limits longer-duration randomized trials,
so only a practice-based population can provide longer
observation [28].
No studies have evaluated the optimal duration of therapy or
whether greater persistency of antidementia drug therapy
affects patient outcomes. We hypothesized that greater
cumulative exposure to the ChEIs or memantine or both
would be associated with slower rates of decline on cognitive
and functional measures in AD patients over the long term.
We assessed the impact of persistent treatment from the
onset of symptoms on key measures of disease progression.
This study was made possible by the longitudinal database at
the Baylor College of Medicine (BCM), in which medication
exposure throughout the disease course is quantified, serial
measurements of cognition and function are collected
annually, and the majority of patients are followed from
diagnosis to death.
Materials and methods
Subjects
All members of this cohort agreed to participate in a
database approved by the institutional review board at BCM
and met criteria for the diagnosis of probable AD as deter-
mined by the National Institute of Neurological and Communi-
cative Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association [29]. All probable AD patients
with at least one complete comprehensive annual follow-up
evaluation were eligible. All patients underwent an evaluation
by a neurologist and completed a standardized dementia
workup that has been in continuous use since 1989 [30]. A
detailed history and interview with the patient and an
informant, neurological and physical examinations, a neuro-
imaging study of the brain, neuropsychological testing, and
screening laboratory studies were performed at the initial
visit. The duration of illness is estimated by the physician by a
standardized procedure reported to the nearest half-year
[31]. We use a standardized method to estimate duration of
illness in AD patients. There is a set of questions for
generating an estimate regarding the date of first symptoms
to the nearest half-year. Physicians revise this estimate in
conjunction with medical record review and patient/informant
interviews and by testing the estimate by recall of life events.
Inter-rater reliability for the estimate has been reported to be
0.95. The initial battery of neuropsychological tests is
repeated along with neurological and physical exams
annually. Each patient’s diagnosis is reviewed at a consensus
conference held weekly at BCM following the baseline and
annual testing. Vital status was obtained from the National
Death Index every 6 months, and the last inquiry was made in
March 2006 with a censoring date for the analysis on 31
December 2005. At censoring, 54% of the cohort had died
and 46% were alive.
Persistency index
Persistent drug exposure was calculated by a persistency
index (PI): total years of drug use divided by the total years of
disease symptoms. This index includes the time period before
the new patient visit. The number of years of disease
symptoms was determined by the physician’s estimate at the
initial visit and extended to the last outcome assessment date.
Exposure
Exposure to the antidementia drugs was ascertained for each
subject. Early drug exposure information (prior to the initial
visit) was recorded by the physician at the first clinic visit by
history obtained from the patient and caregiver along with a
review of medical records. The clinician seeing the patient
completed a drug exposure form at each clinic visit and
recorded all start dates and end dates, if applicable, for useof ChEIs, memantine, and other antidementia drugs. Lapses
in treatment or switching from one drug to another was also
noted and recorded by the treating physician. The dates of
drug exposure were concurrently entered in the electronic
database so the cumulative time on medication could be
determined. We used chart review to complete drug
exposure forms for the subjects who had been seen prior to
the implementation of the drug exposure form in 2002. We
also reconciled any exposure that occurred by virtue of
participation in a clinical research trial by reviewing treatment
assignments and study records. Exposure to antidementia
drugs was calculated in months of use. No attempt was made
to quantify the dose or to distinguish between outcomes on
monotherapy with a ChEI or combination therapy with a ChEI
and glutamate modulator. Historically, ChEIs were widely
available after the introduction of tacrine in 1993, donepezil in
1996, rivastigmine in 2000, and galantamine in 2001.
Combination therapy or multiple-drug use did not often occur
until memantine was approved in October 2003.
Neuropsychological testing
Serial measures of cognition pertinent to this analysis
included the Mini-Mental State Examination (MMSE) [32], a
widely used dementia severity test with scores that range
from 0 to 30 points. Higher scores reflect better perfor-
mance. The Baylor Profound Mental Status Examination
(BPMSE) [33] was administered when the MMSE score was
10 or below. The BPMSE is sensitive to longitudinal change
and evaluates decline in advanced-stage AD when perfor-
mance reaches lowest levels on conventional measures. It is
modeled after the MMSE and consists of 25 patient-derived
cognitive questions that assess orientation, language, atten-
tion, and motor functioning. Higher scores reflect better
cognitive performance. The Alzheimer’s Disease Assessment
Scale-Cognitive Subscale (ADAS-Cog) [34] measures
cognitive domains often impaired in AD, including memory,
language, and praxis. The error score ranges from 0 to 70,
and higher scores reflect greater cognitive impairment. The
ADAS-Cog is thought to be more sensitive to smaller
changes in cognitive function than the MMSE but is less
widely used clinically. The global measure was the Clinical
Dementia Rating-Sum of Boxes (CDR-SB) [35-37]. The
score is derived from a patient interview in conjunction with
an interview of a collateral source. The CDR-SB is obtained
by summing the rating in each of six cognitive domains or
‘boxes’: personal care, affairs in the community and at home,
judgment, orientation, and memory. Higher scores (range 0 to
18) reflect greater global impairment. To evaluate activities of
daily living, we used functional rating scales: the Physical
Self-Maintenance Scale (PSMS) and Instrumental Activities
of Daily Living (IADL) scale [38]. These tests require input
from the caregiver or an informant to evaluate the basic
activities involving physical self-care (PSMS) and perfor-
mance of complex daily functional activities essential to
independence (IADL). The PSMS evaluates six aspects of
self-care: toilet, feeding, dressing, grooming, ambulation, and
bathing. Each item is scored from 1 to 5, and the maximum
score is 30. The IADL evaluates eight complex tasks,
including the use of the telephone, ability to shop, and mode
of transportation. A score of zero can be assigned for five of
the items if the patient did not perform the activity in question
prior to the onset of illness: food preparation, housekeeping,
laundry, ability to handle finances, and responsibility for
medications. The maximum score is 31. Higher scores on the
PSMS and IADL indicate greater functional impairment.
Pre-progression rate
AD patients progress at different rates but little is known
about factors that explain the variance. The pre-progression
rate is an easily calculable index of early disease progression
and has prognostic value in classifying patients as rapid,
intermediate, or slow progressors. It is calculated as (the
MMSE score [expected 30] – MMSE score [initial])/
physician’s estimate of symptom duration (in years). The pre-
progression rate is significant in determining time to clinically
meaningful decline during longitudinal follow-up [39,40]. It
was therefore an important covariate in the current analysis.
Covariates
Age, gender, years of education, baseline severity of
dementia (mild, moderate, or severe based on MMSE score),
pre-progression rate, and an indicator variable reflecting
whether a patient had started on antidementia therapy before
their initial visit to the Alzheimer’s Disease and Memory
Disorders Center. The use of drug prior to the initial visit
(early exposure index) was used to control for the effects of
early treatment or the propensity to take medication or both.
Statistical analysis
Descriptive statistics (that is, frequencies for categorical
variables and means and standard deviations for continuous
variables) for the following variables were determined for the
group as a whole at baseline: gender, age, education,
physician’s estimate of symptom duration, early exposure
index, MMSE, ADAS-Cog, PSMS, IADL, CDR-SB, and
BPMSE. Repeated measurement (random effects) linear
modeling was used to examine the impact of cumulative
antidementia drug exposure (PI) on change in the slope or
rate of decline for the neuropsychological tests. Since this
study focused on cohort average effect, no specific random
effect was added to the model on any particular covariate,
except assuming the existence of correlation between two
outcome observations of the same subject. The correlation
between two observations of any neuropsychological variable
was assumed to follow an autoregressive correlation model
of order 1. This model takes into consideration that the corre-
lation of two observations for each outcome variable is
inversely proportional to the time interval between these two
measurements. The primary model included time from the first
visit, PI, interaction of these two terms, and pre-progression
rate at the initial visit. Adjustments were then made for age,
gender, years of education, baseline severity of dementia
Available online http://alzres.com/content/1/2/7
Page 3 of 7
(page number not for citation purposes)(mild, moderate, or severe based on MMSE score), and early
exposure index (categorical). The outcome data for each
measure were evaluated for significance of the quadratic
relationship, including both linear and quadratic trend change.
The regression coefficient associated with the variable PI
indicated the amount of change in cognitive/functional
performance or change in mean test score associated with a
unit change in the PI at baseline. The regression coefficient
associated with the interaction of time from the first visit and
PI (PI × time) indicated the rate of decline on neuro-
psychological tests or change in the slope associated with a
unit change in the PI.
Results
There were 672 eligible subjects. Among them, 31 did not
have either PI or complete neuropsychological measurements
at any time point and were excluded from the analysis. We
compared the sample of included patients (n = 641) and
those subjects who were missing an important covariate
(n = 31) and found no significant differences in gender, years
of education, age, or number of clinic visits (analysis not
reported). The excluded subjects had a significantly longer
duration of symptoms and higher early exposure index at the
new patient visit (P <0.01). Baseline demographic charac-
teristics were age, gender, years of education and symptom
duration, average follow-up time, number of annual visits, and
the early exposure index (Table 1) and the baseline scores on
the ADAS-Cog, MMSE, BPMSE, IADL, PSMS, and CDR-SB
(Table 2). A frequency analysis of drug exposures in the 641
patients indicated that 43% of the group had been exposed
to drug before the initial visit and 43% began treatment within
2 years following the new patient visit. The percentage of
individuals who were using medication at baseline increased
with the duration of symptoms. Over the entire period of
follow-up, 12% never used medication (Table 3). In the longi-
tudinal data including all visits, there were equal proportions
on a ChEI alone (n = 1,623) or combination therapy of a ChEI
and memantine (n = 1,627) and few taking only memantine
(n = 169).
In a linear model, greater antidementia drug use was signifi-
cantly associated with a slower rate of decline over time on
the MMSE (P <0.0001), ADAS-Cog (P <0.01), PSMS
(P <0.05), IADL (P <0.0001), and CDR-SB (P <0.001).
There was a trend (P = 0.053) indicating that greater anti-
dementia drug was associated with a slower rate of decline
on BPMSE (Table 4, PI × time). Assumptions of linear change
were valid for all of the rating scales except the ADAS-Cog.
Including both linear and quadratic terms in the model for
ADAS-Cog change, we found that greater antidementia drug
use was associated with a slower rate of decline on the
ADAS-Cog for the first 3.3 years and that afterwards the
positive treatment effect diminished.
The magnitude of the treatment effect was clinically relevant.
The rate of change in mean test scores indicated that
maximally treated compared with untreated patients would
have less decline on the rating scales: 1 point per year on the
MMSE, 0.4 points per year on the PSMS, 1.4 points per year
on the IADL, and 0.6 points per year on the CDR-SB. These
treatment effects are additive over the entire period of
observation. After 5 years, maximally treated patients would
retain 4 more points on the MMSE, 2 fewer points on the
PSMS, 3 fewer points on the IADL, and 1.6 fewer points on
the CDR-SB. The benefits are also reflected in the ADAS-
Cog, but properties of this test suggest that after about 3
years the persistent treatment effect is no longer detectable.
Overall, there appears to be incremental benefit associated
with greater cumulative antidementia drug use.
Discussion
Patients who received more persistent exposure to the
antidementia drugs over the course of their illness had a
significantly slower rate of decline on key measures of
cognition, global functioning, and basic activities of daily
Alzheimer’s Research & Therapy    Vol 1 No 2 Rountree et al.
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Table 1
Baseline characteristics of patients with Alzheimer disease 
Variable (n = 641) Value Range
Age, years 73 (8.50) 43-93
Female 68%
Education, years 14 (3.56) 0-29
Early exposure index, years 0.5 (0.27) 0-1
Duration of symptoms before  3.7 (2.29) 0.5-13
initial visit, years
Follow-up time, years 3.0 (1.94) 0.8-13.4
Total number of visits 3.4 (1.64) 2-11
For all continuous variables, values are presented as mean (standard
deviation).
Table 2
Baseline neuropsychological test scores 
Variable (n = 641) Average score Range
MMSE 19.5 (6.64) 0-30
ADAS-Cog 24.3 (12.43) 1-68
BPMSE 19.6 (5.96) 0-25
CDR-SB 6.7 (4.02) 0.5-18
IADL 15.5 (6.50) 2-31
PSMS 7.9 (3.05) 6-25
For all continuous variables, values are presented as mean (standard
deviation). ADAS-Cog, Alzheimer’s Disease Assessment Scale-
Cognitive Subscale; BPMSE, Baylor Profound Mental Status
Examination; CDR-SB, Clinical Dementia Rating-Sum of Boxes; IADL,
Instrumental Activities of Daily Living; MMSE, Mini-Mental State
Examination; PSMS, Physical Self-Maintenance Scale.living. These effects are cumulative over time. Our results are
consistent with a recent 3-year prospective study that com-
pared outpatients taking ChEIs with untreated historical
controls and that found that treatment was associated with
fewer declines on a global dementia rating scale (Clinician
Interview Based Impression of Change) and with significantly
improved cognition as assessed by the MMSE and ADAS-
Cog [41]. Our study indicates that persistent treatment is
associated with positive benefit over the entire course of the
disease and is reflected in both cognitive and functional
outcomes.
One shortcoming of this study is that drug exposure was not
assigned randomly, so we could not explore potential differ-
ences in combinations of antidementia drugs. In addition, we
did not have data on indications for treatment or MMSE
scores before the patients were first evaluated at our center.
The PI was constant (not time-dependent) and did not reflect
the outcome for each patient at each time point. PI as
determined by the last observation was related in the analysis
to earlier cognitive assessments. However, our objective was
to evaluate the cumulative benefit of therapy over the life span
rather than short-term treatment effects. Uncontrolled
variables related to disease severity or duration of symptoms
or both, perceived benefits from treatment, or other un-
measured factors (including behavioral symptoms or medical
comorbidity) may have influenced the observed relationship
between persistency of drug use and outcomes. The fact that
our study included both treated and untreated individuals,
even in subcohorts examined by duration of symptoms and
total follow-up time (Table 3), contributes to the validity of the
findings.
It is possible that individuals who take the antidementia drugs
consistently have naturally slow disease progression and that
their milder disease course could be falsely attributed to drug
treatment. We cannot rule out the possibility that selection
factors related to disease severity or perceived benefits from
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Table 3
Drug exposure and duration of illness 
Duration of  Treatment initiated
symptoms 
at the NPV Before NPV 1-2 years after NPV 3 years after NPV Never treated Total
<2 years 37 (5.8) 49 (7.6) 5 (0.8) 18 (2.8) 109 (17.0)
2-3 years 98 (15.3) 112 (17.5) 10 (1.6) 33 (5.1) 253 (39.5)
4-5 years 79 (12.3) 80 (12.5) 2 (0.3) 13 (2.0) 174 (27.1)
≥6 years 59 (9.2) 34 (5.3) 1 (0.2) 11 (1.7) 105 (16.4)
Total 273 (42.6) 275 (42.9) 18 (2.8) 75 (11.7) 641 (100.0)
Values are presented as number (percentage). NPV, new patient visit.
Table 4
Relationship between persistency index and outcome measures (mixed effects regression analysis) 
Beta coefficientb (standard error)
Outcome(s) with 
adjustmenta Intercept Time, years Persistency index Persistency index × time
MMSE 3.89 (2.001) –2.58 (0.13)c –1.09 (0.77) 1.02 (0.23)c
ADAS-Cogd 55.45 (5.65)c 3.68 (0.66)c –3.75 (2.09) 2.74 (1.32)e
BPMSE 10.46 (3.47)e –2.55 (0.25)c –1.76 (1.90) 1.00 (0.52)
PSMS 10.03 (1.85)c 1.68 (0.12)c –0.09 (0.66) –0.43 (0.21)f
IADL 18.63 (2.54)c 2.36 (0.17)c 4.19 (0.91)c –1.42 (0.29)c
CDR-SB 11.43 (1.43)c 1.67 (0.09)c 1.42 (0.54)e –0.61 (0.17)g
aAdjustment made for early exposure index, gender, education, age, pre-progression rate, and the severity of disease at baseline. bMean change in
score associated with each variable. cP <0.0001. dWhen the linear trend and quadratic trend change were included in the model the coefficients
(standard errors) for time-squared and time-squared by persistency index interaction are 0.19 (0.14) and -0.83 (0.26)e, respectively. eP <0.01;
fP <0.05; gP <0.001; otherwise, P = not significant, based on type 3 F test. ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive
Subscale; BPMSE, Baylor Profound Mental Status Examination; CDR-SB, Clinical Dementia Rating-Sum of Boxes; IADL, Instrumental Activities of
Daily Living; MMSE, Mini-Mental State Examination; PSMS, Physical Self-Maintenance Scale.treatment influenced the observed relationship between
persistency of drug use and outcomes. We adjusted the
analysis by calculating an early exposure index to correct for
the propensity to take medication, but this adjustment may
not fully control the confounding factor. In an exploratory
model that adjusted for the duration of symptoms rather than
the pre-progression rate, we found that taking drug before
the first visit was associated with worse cognitive and
functional tests yet that cumulative drug use remained
beneficial. This suggests that more rapid progressors, rather
than slow progressors, are more likely to have been started
on drug prior to the initial visit.
Conclusions
This study suggests that the more persistent that patients are
and the longer that they persist with treatment the better they
will perform on cognitive, global, and functional outcomes.
The modest findings of one long-duration trial (AD2000) that
included regular washouts of treatment might be explained, in
part, by lack of treatment persistence [16]. The impact of AD
therapy should be judged by the cumulative benefit over the
duration of the disease. Our findings also suggest that
antidementia drugs may benefit patients even when given in
advanced or profound stages of AD.
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